Opinion|Videos|December 17, 2024
Management of Recurrent C Difficile Infections in the Future
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
- Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you see the management of recurrent C difficile infections moving forward?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
CKD Caregiving Drives Social Isolation, Loneliness
5